HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Yoshiya Toyoda Ricardo Santos Duc Nguyen Jay Bhama Christian Bermudez Robert Kormos Kenneth McCurry Marco Zenati Brack Hattler Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Toyoda, Y. Articles by Hattler, B. Search for Related Content PubMed PubMed Citation Articles by Toyoda, Y. Articles by Hattler, B. Related Collections Lung - transplantation

---

Original Articles: General Thoracic

Long-Term Outcome of Lung and Heart-Lung Transplantation for Idiopathic Pulmonary Arterial Hypertension

^a Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
^b Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

Accepted for publication May 15, 2008.

^_* Address correspondence to Dr Toyoda, Cardiothoracic Transplantation, University of Pittsburgh Medical Center, 200 Lothrop Street, C-900 PUH, Pittsburgh, PA 15213 (Email: toyoday{at}upmc.edu).

Background: The survival after lung and heart-lung transplantation for idiopathic pulmonary arterial hypertension has been reportedly the lowest among the major diagnostic categories of lung transplant recipients.

Methods: Retrospective analysis was performed for lung and heart-lung transplant recipients for idiopathic pulmonary arterial hypertension from 1982 to 2006. The patients were divided into 2 groups, based on the era; group 1: 1982 to 1993, and group 2: 1994 to 2006. Since 1994, we have introduced our current protocols including prostaglandin E₁ and nitroglycerin for donor lung preservation, and lung protection with cold and terminal warm blood pneumoplegia as well as immunosuppression with alemtuzumab induction. These modifications were introduced in different years over a wide span of time (1994 to 2003).

Results: Group 1 had 59 patients (35 ± 1 years old, ranging 15 to 53, 20 male and 39 female) with 7 single lung, 11 double lung, and 41 heart-lung, whereas group 2 had 30 (43 ± 2 years old, ranging 17 to 65, 9 male and 21 female) with 2 single, 20 double, and 8 heart-lung transplantations. The recipient age was significantly (p = 0.004) higher in group 2, and group 2 had significantly older (35 ± 3 vs 26 ± 1, p = 0.002) and more female donors (73% vs 41%, p = 0.007) compared with group 1. The actuarial survival was significantly (p = 0.004) better in group 2 with 86% at 1 year, 75% at 5 years, and 66% at 10 years compared with group 1 with 58% at 1 year, 39% at 5 years, and 27% at 10 years.

Conclusions: With our current pulmonary protection and immunosuppression, the long-term outcome of lung and heart-lung transplantation for idiopathic pulmonary arterial hypertension is excellent.

This article has been cited by other articles:

				A. M. Keogh, E. Mayer, R. L. Benza, P. Corris, P. G. Dartevelle, A. E. Frost, N. H. Kim, I. M. Lang, J. Pepke-Zaba, and J. Sandoval Interventional and surgical modalities of treatment in pulmonary hypertension. J. Am. Coll. Cardiol., June 30, 2009; 54(1 Suppl): S67 - S77. [Abstract] [Full Text] [PDF]